Despite blockbuster boasts for R&D work, pressure increases on Pfizer to do a megadeal
Some new products like Ibrance are gaining ground in the marketplace, helping Pfizer weather the storm of generic competition. But sales declined in Q2 as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
